Illumina (NASDAQ:ILMN) Director Sells 68,108 Shares of Stock

04 Sep 2026, 23:09 by Danessa Lincoln · The Markets Daily

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 68,108 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $213.28, for a total value of $14,526,074.24. Following the transaction, the director owned 965,802 shares of the company’s stock, valued at approximately $205,986,250.56. The trade was a 6.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Illumina Price Performance

Shares of ILMN traded down $3.44 during mid-day trading on Friday, hitting $218.22. 1,728,019 shares of the stock were exchanged, compared to its average volume of 1,904,505. The company has a market cap of $32.95 billion, a PE ratio of 40.71, a price-to-earnings-growth ratio of 3.02 and a beta of 1.46. The firm has a 50-day moving average of $197.58 and a two-hundred day moving average of $158.61. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the business earned $1.19 earnings per share. Illumina’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ILMN. Guggenheim increased their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Stifel Nicolaus increased their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Piper Sandler reissued an “overweight” rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Evercore reissued an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $191.31.

Get Our Latest Report on Illumina

Illumina News Summary

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Hedge Funds Weigh In On Illumina

Large investors have recently bought and sold shares of the business. Empowered Funds LLC raised its stake in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after buying an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new position in Illumina in the 2nd quarter valued at about $621,000. CW Advisors LLC purchased a new position in Illumina in the second quarter worth approximately $275,000. Marshall Wace LLP increased its position in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC increased its position in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.